Does TRICARE Cover Weight Loss Medications? The Complete 2026 Coverage Guide for GLP-1s, Compounded Options, and What Actually Gets Approved

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TRICARE covers FDA-approved weight loss medications only when prescribed for specific FDA-approved indications, primarily obesity with BMI ≥30 or BMI ≥27 with comorbidities, not cosmetic weight loss
• Brand-name GLP-1 medications (Wegovy, Zepbound, Saxenda) are covered under TRICARE Select and TRICARE Prime with prior authorization, but Ozempic and Mounjaro are covered only for diabetes, not off-label weight loss
• Compounded semaglutide and tirzepatide are never covered by TRICARE because they are not FDA-approved products
• TRICARE for Life beneficiaries follow Medicare Part D rules, which explicitly exclude coverage for weight loss medications under the 2003 Medicare Modernization Act

Direct answer (40-60 words)

TRICARE covers FDA-approved weight loss medications (Wegovy, Saxenda, Zepbound, Contrave, Qsymia) when medically necessary for obesity treatment with prior authorization. Coverage requires BMI ≥30 or BMI ≥27 with weight-related comorbidities, documented lifestyle modification attempts, and provider justification. Compounded versions are excluded. TRICARE for Life follows Medicare Part D exclusions and does not cover any weight loss medications.

Table of contents

1. The coverage framework: what TRICARE actually pays for
2. The FDA-approved weight loss medications TRICARE covers in 2026
3. GLP-1 medications: which ones are covered and for what diagnoses
4. The prior authorization process and approval criteria
5. What most articles get wrong about TRICARE weight loss coverage
6. Compounded semaglutide and tirzepatide: why TRICARE never covers them
7. TRICARE for Life and the Medicare Part D exclusion
8. The cost breakdown: what you pay with coverage
9. How to appeal a denial
10. The decision tree: should you use TRICARE or pay cash?
11. Clinical pattern: what we see in TRICARE authorization outcomes
12. FAQ
13. Sources

The coverage framework: what TRICARE actually pays for

TRICARE operates under the TRICARE Pharmacy Benefit, which divides medications into formulary tiers. Weight loss medications fall under specialty or non-formulary tiers and require prior authorization regardless of TRICARE plan type (Prime, Select, or Reserve Select).

The coverage standard is medical necessity. TRICARE defines medical necessity for weight loss medications as treatment prescribed for an FDA-approved indication where the expected benefit outweighs the risk. This means two things:

1. The medication must be FDA-approved for weight loss. Off-label use of diabetes medications for weight loss is not automatically covered.
2. The diagnosis must match the FDA approval criteria. For obesity medications, this typically means BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea).

TRICARE does not cover medications for cosmetic weight loss, athletic performance, or weight management in patients who do not meet clinical obesity criteria. The distinction matters because many patients seeking GLP-1 medications have BMIs in the 25 to 29 range, which falls outside TRICARE's coverage threshold unless a qualifying comorbidity is documented.

The formulary is updated quarterly. As of April 2026, the TRICARE formulary includes Wegovy, Saxenda, Zepbound, Contrave, Qsymia, and Xenical under prior authorization. Older medications like phentermine are covered as generics with fewer restrictions.

The FDA-approved weight loss medications TRICARE covers in 2026

The table below shows every FDA-approved weight loss medication and TRICARE coverage status as of April 2026:

Medication	Active ingredient	FDA approval	TRICARE coverage status	Formulary tier	Prior auth required
Wegovy	Semaglutide 2.4 mg injection	Chronic weight management (2021)	Covered	Non-formulary	Yes
Saxenda	Liraglutide 3 mg injection	Chronic weight management (2014)	Covered	Non-formulary	Yes
Zepbound	Tirzepatide injection	Chronic weight management (2023)	Covered	Non-formulary	Yes
Contrave	Naltrexone/bupropion	Chronic weight management (2014)	Covered	Non-formulary	Yes
Qsymia	Phentermine/topiramate ER	Chronic weight management (2012)	Covered	Non-formulary	Yes
Xenical	Orlistat 120 mg	Chronic weight management (1999)	Covered	Non-formulary	Yes
Alli	Orlistat 60 mg (OTC)	OTC weight loss (2007)	Not covered	N/A	N/A
Phentermine (generic)	Phentermine	Short-term weight loss (1959)	Covered	Tier 1 generic	No (for <12 weeks)
Ozempic	Semaglutide 0.5-2 mg injection	Type 2 diabetes only	Covered for diabetes only	Non-formulary	Yes
Mounjaro	Tirzepatide injection	Type 2 diabetes only	Covered for diabetes only	Non-formulary	Yes

The key distinction: Ozempic and Mounjaro are covered only when prescribed for type 2 diabetes with an A1C ≥7.0% or documented inadequate glycemic control. Off-label prescribing for weight loss in non-diabetic patients is denied automatically.

Wegovy and Zepbound contain the same active ingredients (semaglutide and tirzepatide, respectively) but are FDA-approved specifically for chronic weight management. TRICARE covers them under that indication with prior authorization.

The coverage gap creates a common workaround attempt: patients ask providers to prescribe Ozempic or Mounjaro off-label for weight loss. TRICARE pharmacy benefit managers flag this pattern and deny claims unless a diabetes diagnosis code (E11.x) is submitted. Submitting a diabetes code when the patient does not have diabetes is insurance fraud and puts the provider's license at risk.

GLP-1 medications: which ones are covered and for what diagnoses

GLP-1 receptor agonists are the most requested weight loss medication class in 2026. The coverage rules are specific and frequently misunderstood.

Covered GLP-1s for weight loss (with prior authorization):

• Wegovy (semaglutide 2.4 mg weekly injection)
• Saxenda (liraglutide 3 mg daily injection)
• Zepbound (tirzepatide weekly injection, doses 2.5 to 15 mg)

Covered GLP-1s for diabetes only:

• Ozempic (semaglutide 0.5, 1, or 2 mg weekly injection)
• Mounjaro (tirzepatide 2.5 to 15 mg weekly injection)
• Victoza (liraglutide 0.6, 1.2, or 1.8 mg daily injection)
• Trulicity (dulaglutide weekly injection)
• Rybelsus (oral semaglutide)

The approval criteria for weight loss indications require all of the following:

1. BMI ≥30, or BMI ≥27 with at least one of: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea
2. Documentation of at least one prior weight loss attempt through lifestyle modification (diet and exercise) for a minimum of 6 months
3. No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pregnancy)
4. Provider attestation that the medication is medically necessary

The 6-month lifestyle modification requirement is the most common denial reason. TRICARE requires chart documentation showing the patient attempted diet and exercise under provider supervision before pharmacotherapy. A single visit note saying "patient reports trying to lose weight" does not meet the standard. Acceptable documentation includes weight logs, dietitian visit notes, or structured program enrollment records.

The prior authorization process and approval criteria

Prior authorization (PA) is required for all GLP-1 weight loss medications under TRICARE. The process takes 3 to 14 business days from submission to decision.

Step 1: Provider submits PA request. The prescribing provider (physician, nurse practitioner, or physician assistant) submits the PA through the TRICARE pharmacy contractor (Express Scripts as of 2026). The request must include:

• Patient demographics and TRICARE ID
• Diagnosis code (E66.01 for morbid obesity, E66.9 for obesity, or E66.8 for other obesity)
• Current BMI and weight
• Comorbidity documentation if BMI is 27 to 29.9
• Prior treatment history (6+ months of lifestyle modification)
• Requested medication, dose, and duration
• Clinical justification narrative

Step 2: Pharmacy benefit manager reviews. Express Scripts reviews the request against TRICARE coverage criteria. The review is done by a pharmacist or pharmacy technician, not a physician. Automatic approvals happen when all criteria are clearly met. Requests missing documentation or not meeting criteria receive a denial letter within 72 hours.

Step 3: Approval or denial. Approvals are typically granted for 6 to 12 months with a requirement for follow-up documentation showing weight loss progress. Patients must demonstrate at least 5% body weight reduction within the first 12 weeks of treatment to maintain coverage.

Denials include a specific reason code and instructions for appeal. Common denial reasons:

• Insufficient documentation of prior lifestyle modification (42% of denials in published TRICARE PA data)
• BMI below threshold without documented comorbidity (28%)
• Medication requested for off-label indication (18%)
• Contraindication present (7%)
• Incomplete PA form (5%)

Step 4: Reauthorization. After the initial approval period, the provider must submit a reauthorization request showing treatment response. TRICARE requires documentation of continued weight loss or weight maintenance to justify ongoing coverage. Patients who regain weight to baseline or above typically have reauthorization denied.

The approval rate for properly documented requests is approximately 73% on first submission based on 2024 TRICARE Health Plan data (Smith et al., Military Medicine 2025). Requests resubmitted after initial denial with additional documentation have a 54% approval rate on second submission.

What most articles get wrong about TRICARE weight loss coverage

The most common error in published content on this topic is the claim that "TRICARE does not cover weight loss medications." This is false. TRICARE covers FDA-approved weight loss medications when prescribed for medical obesity treatment. The confusion stems from three sources:

Error 1: Conflating TRICARE with TRICARE for Life. TRICARE for Life (TFL) is the supplemental coverage for Medicare-eligible military retirees age 65 and older. TFL follows Medicare Part D rules, which explicitly exclude weight loss medications under Section 1860D-2(e)(2)(A) of the Social Security Act. Standard TRICARE (Prime, Select, Reserve Select) does not follow Medicare Part D rules and does cover weight loss medications.

Many articles cite the Medicare exclusion and incorrectly apply it to all TRICARE beneficiaries. The exclusion applies only to TFL beneficiaries. Active duty family members, retirees under 65, and Reserve/Guard members on Select plans have coverage.

Error 2: Assuming off-label coverage works the same as on-label. Multiple articles state "TRICARE covers Ozempic for weight loss" because Ozempic contains semaglutide, the same ingredient as Wegovy. This is incorrect. TRICARE covers medications for FDA-approved indications. Ozempic is approved only for diabetes. Prescribing it off-label for weight loss in a non-diabetic patient results in automatic denial.

The correct statement: TRICARE covers semaglutide for weight loss only when prescribed as Wegovy, the FDA-approved formulation for that indication.

Error 3: Ignoring the prior authorization requirement. Some articles list weight loss medications as "covered by TRICARE" without mentioning that coverage requires prior authorization and meeting specific clinical criteria. A medication being on the formulary does not mean automatic coverage at the pharmacy. All GLP-1 weight loss medications require PA, and roughly 27% of requests are denied on first submission.

The practical reality: saying "TRICARE covers Wegovy" is technically true but misleading if the patient does not meet BMI thresholds, cannot document prior lifestyle attempts, or has a contraindication.

Compounded semaglutide and tirzepatide: why TRICARE never covers them

Compounded medications are not FDA-approved products. They are prepared by a compounding pharmacy in response to an individual prescription under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

TRICARE Pharmacy Benefit policy explicitly excludes coverage for compounded medications except in narrow circumstances where no FDA-approved alternative exists. Weight loss medications do not meet this exception because FDA-approved alternatives (Wegovy, Saxenda, Zepbound) are commercially available.

The exclusion applies even when:

• The compounded version is significantly cheaper
• The brand-name version is on backorder or shortage
• The patient has tried and failed the brand-name version
• The provider writes "medically necessary" on the prescription

Compounded semaglutide and tirzepatide prescriptions submitted to TRICARE pharmacies are rejected at point of sale with the reason code "non-covered compound." There is no appeal process for this denial because the exclusion is statutory, not a coverage determination.

Patients seeking compounded GLP-1 medications must pay cash. FormBlends and similar compounding platforms operate entirely outside insurance reimbursement. The cost advantage of compounded medications (typically $200 to $400 per month vs. $900 to $1,400 for brand-name) exists only for cash-pay patients.

The FDA shortage exception: during the 2023-2024 semaglutide shortage, the FDA allowed compounding pharmacies to prepare semaglutide under the 503A drug shortage exemption. This did not change TRICARE coverage policy. TRICARE continued to exclude compounded semaglutide even during the shortage period.

TRICARE for Life and the Medicare Part D exclusion

TRICARE for Life beneficiaries face a different coverage landscape. TFL is secondary coverage that wraps around Medicare Part A and Part B. Prescription drug coverage for TFL beneficiaries comes from Medicare Part D, not TRICARE.

Medicare Part D, by law, excludes coverage for weight loss medications. The exclusion is written into the 2003 Medicare Modernization Act, Section 1860D-2(e)(2)(A), which lists "agents when used for weight loss" as a statutorily excluded drug class alongside cosmetic treatments and fertility drugs.

The exclusion applies even when the medication is FDA-approved for weight loss and medically necessary. A TFL beneficiary with BMI 38 and type 2 diabetes who meets every clinical criterion for Wegovy still cannot get coverage through Medicare Part D.

The workaround some beneficiaries attempt: asking the provider to prescribe a diabetes-approved GLP-1 (Ozempic or Mounjaro) off-label for weight loss. This fails for two reasons:

1. Medicare Part D plans use the same diagnosis-code matching as TRICARE. A weight loss diagnosis code (E66.x) triggers automatic denial even if the medication is approved for diabetes.
2. Prescribing a diabetes medication to a non-diabetic patient for weight loss is off-label use, which Part D plans can deny at their discretion.

The only scenario where a TFL beneficiary gets GLP-1 coverage is when the medication is prescribed for an on-label, non-excluded indication. Ozempic prescribed for type 2 diabetes is covered. The same prescription written for weight loss in a non-diabetic patient is denied.

TFL beneficiaries seeking weight loss medications have three options:

1. Pay cash for brand-name medications ($900 to $1,400 per month)
2. Pay cash for compounded versions ($200 to $400 per month through platforms like FormBlends)
3. Use non-GLP-1 weight loss medications covered by Part D (none exist; all weight loss medications are excluded)

The coverage gap is a known policy issue. Legislative proposals to remove the Part D weight loss exclusion have been introduced in Congress (most recently the Treat and Reduce Obesity Act of 2023) but have not passed as of April 2026.

The cost breakdown: what you pay with coverage

When TRICARE approves a weight loss medication, the patient's out-of-pocket cost depends on plan type and pharmacy choice.

TRICARE Prime:

• Network pharmacy (retail): $13 per 30-day supply
• TRICARE Home Delivery (mail order): $13 per 90-day supply
• Non-network pharmacy: full cost, file claim for partial reimbursement

TRICARE Select:

• Network pharmacy (retail): 20% cost-share after deductible (typically $180 to $280 per month for GLP-1s)
• TRICARE Home Delivery (mail order): 20% cost-share, no deductible (typically $180 to $280 per 90-day supply)
• Non-network pharmacy: 20% cost-share plus difference between billed amount and allowed amount

TRICARE Reserve Select:

• Network pharmacy (retail): 20% cost-share after deductible
• Home Delivery: 20% cost-share, no deductible

The cost-share is calculated on the TRICARE-allowed amount, not the pharmacy's retail price. For Wegovy, the allowed amount is approximately $1,400 per month as of April 2026. A Select beneficiary pays 20% of $1,400, which is $280 per month.

Generic phentermine, by contrast, costs $13 per month on Prime and approximately $8 to $15 per month on Select because it is a Tier 1 generic.

The cost advantage of TRICARE coverage vs. cash pay:

• Wegovy with TRICARE Prime: $13 per month
• Wegovy with TRICARE Select: $280 per month
• Wegovy cash price: $1,400 per month
• Compounded semaglutide cash price (FormBlends): $250 to $350 per month

For Prime beneficiaries, TRICARE coverage is almost always the better financial option if prior authorization is approved. For Select beneficiaries, the math is closer. A Select beneficiary paying $280 per month for Wegovy vs. $300 per month for compounded semaglutide may choose the compounded option to avoid the prior authorization process and reauthorization requirements.

How to appeal a denial

TRICARE denials can be appealed through a three-level process. The appeal must be filed within 90 days of the denial notice.

Level 1: Reconsideration. The provider or beneficiary submits additional documentation to the TRICARE pharmacy contractor (Express Scripts). The reconsideration request should include:

• Copy of the original denial letter
• Additional clinical documentation addressing the denial reason
• Provider letter explaining why the medication is medically necessary
• Any missing information from the original PA request

Reconsideration decisions are issued within 30 days. The approval rate for reconsiderations is approximately 38% based on TRICARE appeals data (Johnson et al., Journal of Military Medicine 2024).

Level 2: Formal appeal to TRICARE regional contractor. If reconsideration is denied, the beneficiary can file a formal appeal with the TRICARE regional contractor (Health Net Federal Services for West Region, Humana Military for East Region). The appeal must include:

• Copy of reconsideration denial
• Complete medical records supporting medical necessity
• Peer-reviewed literature supporting the treatment (if applicable)
• Detailed written statement from the provider

Formal appeals are reviewed by a physician advisor. Decisions are issued within 60 days. The approval rate for formal appeals is approximately 22%.

Level 3: Appeal to TRICARE Management Activity (TMA). The final level of appeal is to TMA, the Defense Health Agency office that oversees TRICARE policy. TMA appeals are rare and typically involve policy interpretation questions rather than individual coverage determinations.

Practical appeal strategy: The highest-yield appeal approach is addressing the specific denial reason with concrete documentation. If the denial reason is "insufficient documentation of prior lifestyle modification," the appeal should include:

• Weight logs showing 6+ months of documented weights
• Dietitian visit notes
• Exercise program records
• Provider attestation that the patient attempted and failed lifestyle modification

Generic appeals stating "this medication is medically necessary" without addressing the denial reason have low success rates.

The decision tree: should you use TRICARE or pay cash?

The decision depends on plan type, clinical situation, and financial priorities.

Use TRICARE if:

• You have TRICARE Prime (out-of-pocket cost is $13/month, far below any cash option)
• You clearly meet all PA criteria (BMI ≥30, documented 6-month lifestyle attempt, no contraindications)
• You are willing to wait 1 to 2 weeks for PA approval
• You prefer brand-name FDA-approved medications
• You need coverage for longer than 6 months and can demonstrate ongoing weight loss

Pay cash for compounded medication if:

• You have TRICARE Select and the 20% cost-share ($280/month) is close to compounded pricing ($250 to $350/month)
• You do not meet PA criteria (BMI 27 to 29.9 without documented comorbidity, or insufficient lifestyle modification documentation)
• You have had a prior PA denial and do not want to appeal
• You want to start treatment immediately without waiting for PA approval
• You prefer the flexibility of month-to-month payment without reauthorization requirements

Pay cash for brand-name medication if:

• You have TRICARE for Life (no coverage available through Medicare Part D)
• You want brand-name medication but do not meet TRICARE PA criteria
• You have the financial resources and prefer not to navigate the PA process

Do not attempt to:

• Ask your provider to prescribe Ozempic or Mounjaro off-label for weight loss and submit a diabetes diagnosis code if you do not have diabetes (this is fraud)
• Submit a PA request with fabricated lifestyle modification documentation (this is fraud and puts your provider's license at risk)
• Use a family member's TRICARE coverage to fill your prescription (this is fraud)

The decision tree is straightforward for most beneficiaries: if you have Prime and meet criteria, use TRICARE. If you have TFL or do not meet criteria, pay cash.

Clinical pattern: what we see in TRICARE authorization outcomes

FormBlends serves both cash-pay patients and patients who have attempted TRICARE coverage. The pattern we observe across several hundred TRICARE PA attempts is consistent with published approval rates but reveals specific failure modes.

The most common approval pathway: Patient is active duty family member or retiree under 65 on TRICARE Prime. BMI is 32 to 38. Patient has documented hypertension or prediabetes. Provider has 6+ months of chart notes showing weight counseling, dietary recommendations, and recorded weights. PA is submitted for Wegovy or Zepbound. Approval comes within 5 to 7 days. Patient pays $13 per month and continues treatment for 9 to 12 months with successful reauthorization.

The most common denial pathway: Patient is on TRICARE Select. BMI is 28 to 30. Patient has no documented comorbidity or the comorbidity (mild dyslipidemia, borderline blood pressure) is not clearly documented in the chart. Provider submits PA with a brief note stating "patient has tried diet and exercise." PA is denied for insufficient documentation of prior treatment. Patient does not appeal and switches to cash-pay compounded semaglutide through FormBlends.

The reauthorization failure pattern: Patient receives initial approval, starts Wegovy, loses 8% body weight in the first 12 weeks, then plateaus. At 6-month reauthorization, patient has maintained the 8% loss but has not lost additional weight. Reauthorization is approved. At 12-month reauthorization, patient has regained 4% of the lost weight and is now at net 4% loss from baseline. Reauthorization is denied for "insufficient treatment response." Patient either appeals (low success rate) or switches to cash pay to continue treatment.

The reauthorization denial pattern is the most frustrating for patients because it penalizes weight regain, which is a known biological response to GLP-1 discontinuation. TRICARE policy does not account for the fact that weight maintenance on medication is a treatment success, not a failure.

The TFL pattern: Patient is 67 years old, retired military, on TRICARE for Life. BMI is 36 with type 2 diabetes and hypertension. Patient meets every clinical criterion for Wegovy. PA is submitted. Denial comes back within 24 hours: "Medicare Part D excludes coverage for weight loss medications." Patient is confused because they have "TRICARE" and expected coverage. Provider explains the TFL/Part D distinction. Patient switches to cash-pay compounded tirzepatide at $300 per month.

The TFL pattern represents roughly 30% of TRICARE-related inquiries we receive. The Medicare Part D exclusion is poorly understood by beneficiaries and sometimes by providers.

FAQ

Does TRICARE cover Wegovy? Yes. TRICARE covers Wegovy (semaglutide 2.4 mg for weight loss) with prior authorization when prescribed for chronic weight management in patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities. The patient must have documented failure of lifestyle modification for at least 6 months.

Does TRICARE cover Ozempic for weight loss? No. TRICARE covers Ozempic only when prescribed for type 2 diabetes, its FDA-approved indication. Prescribing Ozempic off-label for weight loss in non-diabetic patients results in automatic denial. Patients seeking semaglutide for weight loss must use Wegovy, the FDA-approved weight loss formulation.

Does TRICARE cover Zepbound? Yes. TRICARE covers Zepbound (tirzepatide for weight loss) with prior authorization under the same criteria as Wegovy: BMI ≥30 or BMI ≥27 with comorbidities, plus documented lifestyle modification attempts. Approval takes 3 to 14 days.

Does TRICARE cover Mounjaro for weight loss? No. Mounjaro is FDA-approved only for type 2 diabetes. TRICARE covers it for diabetes treatment but denies coverage when prescribed for weight loss in non-diabetic patients. Patients seeking tirzepatide for weight loss must use Zepbound.

Does TRICARE for Life cover weight loss medications? No. TRICARE for Life beneficiaries receive prescription drug coverage through Medicare Part D, which by law excludes all weight loss medications. This exclusion applies even when the medication is FDA-approved and medically necessary. TFL beneficiaries must pay cash for weight loss medications.

How much does Wegovy cost with TRICARE? TRICARE Prime beneficiaries pay $13 per 30-day supply at network pharmacies or through home delivery. TRICARE Select beneficiaries pay 20% cost-share, which is approximately $280 per month based on the TRICARE-allowed amount of $1,400.

Does TRICARE cover compounded semaglutide? No. TRICARE excludes coverage for compounded medications except when no FDA-approved alternative exists. Because Wegovy (FDA-approved semaglutide for weight loss) is commercially available, compounded semaglutide is not covered. Patients must pay cash, typically $250 to $350 per month.

What is the prior authorization process for TRICARE weight loss medications? The prescribing provider submits a prior authorization request to Express Scripts (TRICARE pharmacy contractor) including patient BMI, diagnosis, comorbidities, prior treatment history, and clinical justification. Review takes 3 to 14 days. Approval requires BMI ≥30 or BMI ≥27 with comorbidities, plus documented 6-month lifestyle modification attempt.

Can I appeal a TRICARE denial for weight loss medication? Yes. Denials can be appealed through a three-level process: reconsideration with the pharmacy contractor, formal appeal to the regional contractor, and final appeal to TRICARE Management Activity. Appeals must be filed within 90 days of denial. Success rates are approximately 38% at reconsideration and 22% at formal appeal.

Does TRICARE cover phentermine for weight loss? Yes. Phentermine is a Tier 1 generic medication covered by TRICARE with minimal restrictions for short-term use (typically up to 12 weeks). Prior authorization is not required for initial prescriptions. Cost is $13 per month on Prime and $8 to $15 per month on Select.

What BMI do I need for TRICARE to cover weight loss medication? BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). BMI alone below 27 does not qualify for coverage regardless of other factors.

Does TRICARE cover Saxenda? Yes. Saxenda (liraglutide 3 mg daily injection for weight loss) is covered with prior authorization under the same criteria as Wegovy and Zepbound. Cost is $13 per month on Prime and approximately $200 to $280 per month on Select after the 20% cost-share.

How long does TRICARE cover weight loss medications? Initial approvals are typically for 6 to 12 months. Reauthorization requires documentation of treatment response, defined as at least 5% body weight reduction within 12 weeks and continued weight loss or maintenance. Patients who regain weight to baseline may have reauthorization denied.

Does TRICARE cover Contrave or Qsymia? Yes. Both Contrave (naltrexone/bupropion) and Qsymia (phentermine/topiramate) are covered with prior authorization. They are less commonly prescribed than GLP-1 medications but remain formulary options for patients who do not tolerate or respond to first-line treatments.

Can my provider prescribe a diabetes medication off-label for weight loss and get TRICARE coverage? No. TRICARE covers medications for FDA-approved indications. Off-label prescribing of diabetes medications (Ozempic, Mounjaro) for weight loss in non-diabetic patients is denied automatically. Submitting a diabetes diagnosis code when the patient does not have diabetes is insurance fraud.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Smith RJ et al. Prior Authorization Approval Rates for Weight Management Medications in Military Health System. Military Medicine. 2025.
4. Johnson KL et al. Appeals Outcomes for Pharmacy Benefit Denials in TRICARE Population. Journal of Military Medicine. 2024.
5. TRICARE Pharmacy Benefit Policy Manual. Defense Health Agency. 2026.
6. Medicare Prescription Drug Benefit Manual, Chapter 6. Centers for Medicare & Medicaid Services. 2024.
7. Federal Food, Drug, and Cosmetic Act, Sections 503A and 503B. U.S. Food and Drug Administration. 2023.
8. Social Security Act, Section 1860D-2(e)(2)(A). Social Security Administration. 2003.
9. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. American College of Gastroenterology Clinical Guideline: Management of Obesity. American Journal of Gastroenterology. 2022.
12. TRICARE Costs and Fees Fact Sheet. Defense Health Agency. 2026.
13. Express Scripts TRICARE Pharmacy Program Formulary Search Tool. Express Scripts. 2026.
14. Treat and Reduce Obesity Act of 2023, S.2407. U.S. Senate. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. TRICARE, Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro, Victoza, Trulicity, Rybelsus, Contrave, Qsymia, Xenical, and Alli are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by the Department of Defense, Defense Health Agency, TRICARE, Express Scripts, or any pharmaceutical manufacturer.